GOSS News
Archived Headlines
- US IPO Weekly Recap: Gossamer Bio launches 20-day IPO, with more IPOs coming 01/25/19
- Gossamer Bio sets terms for $230 million IPO, bypassing shutdown with rarely-used 20-day rule 01/23/19
- These will be the first IPOs of 2019 01/09/19
- Tis the season for big biotechs: Gossamer Bio files for a $265 million IPO 12/21/18
US IPO Weekly Recap: Two billion-dollar biotechs cap a mixed week for biotech IPOs
In the second week after the SEC opened we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP),...read more
Gossamer Bio prices upsized IPO at $16
Gossamer Bio, which is developing in-licensed immunotherapies for asthma and other indications, raised $276 million by offering an upsized 17.3 million shares at $16, the indicated IPO price. Insiders indicated an interest in purchasing $100 million (36% of deal...read more
2 billion-dollar biotechs will IPO this week; here's how the last 5 performed
One prediction from our 2018 Annual IPO Review is already coming true: Biotech IPOs are getting bigger. Two...read more
US IPO Week Ahead: 2 billion-dollar biotechs in a 4-IPO week
Four IPOs plan to raise $523 million in the week ahead. Biotechs are still a strong force in the IPO market with three early-stage immunotherapy plays on the docket, including two with proposed billion-dollar valuations. A micro-cap Florida bank rounds out the...read more